Meet Renjie Jin, Ferring Innovation Grant recipient
Title: Research Assistant Professor, MD. PhD, Vanderbilt University Medical Center, US
Research Project: Sensitizing castration-resistant prostate cancer to anti-androgens by targeting gastrin-releasing peptide (GRP) receptor
In our department, physicians and basic science researchers work together to solve research questions to ultimately improve patient care in the future. With this project, we aim to develop a new therapeutic approach to control castration-resistant prostate cancer (CRPC).
What motivated you to research this area? Once prostate cancer has become metastatic – once it has spread into different areas of the body - androgen deprivation therapy (ADT) is the main treatment. This treatment leads to clinical improvement in more than 90% of patients, however, it is not a cure. The median duration of response to ADT is approximately 18 to 24 months, after which almost all patients will progress to a more aggressive form of the disease termed castration-resistant, or hormone-resistant, prostate cancer. We want to help this group of patients.
Most exciting thing about your research project? We believe that this study holds enormous potential to define a new class of therapeutics for castration-resistant prostate cancer that even the new generation of drugs cannot treat. It is extremely exciting and rewarding to know that our work could help so many people. The fact that our research may extend and even save lives in the future keeps us grounded and motivated.
How would you describe yourself in 3 words? A urologist, a scientist, an investigator.
Interesting fact about yourself? I have over 20 years’ experience in prostate cancer basic research. Outside of the lab, I volunteer at our church, and play golf, when I have time!
Visit www.ferring-research.com/ferring-grants to learn more about the Ferring Innovation Grants Program.